The Amortization of Funding Gene Therapies: Making the “Intangibles” Tangible for Patients

Abstract excerpt

Gene replacement therapies (GRTs) are increasingly expected to reach the market. Current healthcare systems are struggling to fund such valuable, costly therapies. GRTs are highly valuable as they extend life through sustained, long-term efficacy or by saving on the costs of a current high-cost standard of care. Some payers have implemented payment models, which do not address the budget impact on the year of acqu...

Topics

Open a Topic to create a Post that cites this publication.

• Biomedical Ethics and Regulation
• Biotechnology and Related Fields
• CAR-T cell therapy research
• Health Systems, Economic Evaluations, Quality of Life

Identifiers and source

Literature Corpus work

793c690a-444f-5515-b5d7-c8a9c0d15adb

DOI

10.1101/2021.04.16.21255597